RBC Capital initiated coverage of Becton Dickinson (BDX) with a Sector Perform rating and $211 price target The firm believes Becton is positioning itself for a next phase of growth with the business separation in Q1 of 2026. It cites the company’s “conservative” fiscal 2026 outlook with limited earnings growth until 2027 and more attractive opportunities elsewhere in medical technology for the neutral rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson teams with Henry Ford Health on robotic pharmaceutical solution
- Becton Dickinson Secures $2.75 Billion Credit Facility
- BDX Advances Safety with New Clinical Study on PosiFlush™ SafeScrub
- BD PosiFlush™ SafeScrub Study: A Potential Game-Changer for Medical Device Safety
- Jeffrey Smith’s Starboard Value buys TripAdvisor in Q2